Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) Assets Average: 2018-2025

Historic Assets Average for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $1.1 billion.

  • Denali Therapeutics' Assets Average fell 24.85% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 24.85%. This contributed to the annual value of $1.3 billion for FY2024, which is 3.29% down from last year.
  • Denali Therapeutics' Assets Average amounted to $1.1 billion in Q3 2025, which was down 8.85% from $1.2 billion recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Assets Average ranged from a high of $1.6 billion in Q1 2021 and a low of $1.1 billion during Q3 2025.
  • In the last 3 years, Denali Therapeutics' Assets Average had a median value of $1.4 billion in 2023 and averaged $1.3 billion.
  • As far as peak fluctuations go, Denali Therapeutics' Assets Average surged by 152.35% in 2021, and later decreased by 24.85% in 2025.
  • Denali Therapeutics' Assets Average (Quarterly) stood at $1.4 billion in 2021, then decreased by 5.83% to $1.3 billion in 2022, then declined by 11.06% to $1.2 billion in 2023, then increased by 18.30% to $1.4 billion in 2024, then declined by 24.85% to $1.1 billion in 2025.
  • Its Assets Average was $1.1 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.